News Headlines Now

Delveinsight Business Research LLP

The Polycythemia Vera market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Polycythemia Vera: An Overview

Polycythemia Vera (PV) is a condition characterized by an increased number of red blood cells in the bloodstream (erythrocytosis) and affected people may also have excess white blood cells and platelets. Most cases of PV are not inherited and are acquired during a person’s lifetime.

Polycythemia Vera is diagnosed by testing the blood for levels of a hormone called erythropoietin as well as testing the blood for mutations in JAK2 or TET2. If mutations are not found in the red blood cells but the doctors still suspect a diagnosis of polycythemia vera, a bone marrow biopsy may be done to look for mutations in the hematopoietic blood cells which are located in the bone marrow.

Polycythemia Vera Market Key Facts

• According to DelveInsight, the total prevalent population of polycythemia vera (PV) in the 7MM was found to be 296,000+ in 2020.

• Most of the prevalence of Polycythemia Vera was found in the United States with 166,200+ cases in 2020.

• Among the European 5 countries, Germany had the highest symptomatic prevalent population of Polycythemia Vera with 14,700+ cases, followed by France and the United Kingdom, in 2020. On the other hand, Spain had the lowest symptomatic prevalent population of 7,600+ in 2020.

• Japan had 19,400+ symptomatic prevalent cases for Polycythemia Vera in 2020.

• A higher percentage of symptomatic prevalence was observed for males, in comparison to females, in all the 7MM countries. 

Polycythemia Vera Therapeutic Market

As per DelveInsight, the therapeutic market of Polycythemia Vera in the seven major markets was assessed to be USD 1,480.08 Million in 2020 and is expected to grow during the study period.

Among EU Countries, Germany accounted for the largest market size of PV in 2020, followed by France and the United Kingdom. In contrast, Spain had the smallest market size of PV.

Polycythemia Vera Market

The Polycythemia Vera market size is expected to increase at a significant CAGR during the study period owing to the launch of emerging therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Polycythemia Vera market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Polycythemia Vera market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Polycythemia Vera Epidemiology

The epidemiology section covers insights about the historical and current Polycythemia Vera patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Polycythemia Vera Epidemiology Segmentation

• Total Prevalence of Polycythemia Vera  

• Prevalence Population of Polycythemia Vera Based on Symptoms

• Gender-specific Symptomatic Prevalence of Polycythemia Vera

• Age-specific Symptomatic Prevalence of Polycythemia Vera

• Prevalence of Polycythemia Vera Based on Risk

• Prevalence of Polycythemia Vera by Gene Mutation

Polycythemia Vera Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polycythemia Vera market or expected to get launched in the market during the study period. The analysis covers Polycythemia Vera market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Polycythemia Vera Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/polycythemia-vera-market

Polycythemia Vera Therapeutics Analysis

Globally, some of the key companies are involved in the development of therapies for the Polycythemia Vera, the therapies are under different stages of development and are expected to launch in the coming years. 

Key Companies in the Polycythemia Vera Market Includes:

• Italfarmaco 

• Imago BioSciences 

• Protagonist Therapeutics 

And others

Polycythemia Vera Therapies covered in the report includes:

• PTG-300

• Givinostat; ITF2357

• Bomedemstat/IMG-7289

And many more.

Get More Detailed Insights into the Emerging Therapies & Key Companies:-  https://www.delveinsight.com/sample-request/polycythemia-vera-market

Table of Content

1. Key Insights

2. Executive Summary 

3. Polycythemia Vera Competitive Intelligence Analysis

4. Polycythemia Vera Market Overview at a Glance

5. Polycythemia Vera Disease Background and Overview

6. Polycythemia Vera Patient Journey

7. Polycythemia Vera Epidemiology and Patient Population

8. Polycythemia Vera Treatment Algorithm, Current Treatment, and Medical Practices

9. Polycythemia Vera Unmet Needs

10. Key Endpoints of Polycythemia Vera Treatment

11. Polycythemia Vera Marketed Products

12. Polycythemia Vera Emerging Therapies

13. Polycythemia Vera Seven Major Market Analysis

14. Attribute Analysis

15. Polycythemia Vera Market Outlook (7 major markets)

16. Polycythemia Vera Access and Reimbursement Overview

17. KOL Views on the Polycythemia Vera Market.

18. Polycythemia Vera Market Drivers

19. Polycythemia Vera Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/polycythemia-vera-market

Other Latest Healthcare Reports By DelveInsight

Malignant Pleural Mesothelioma (MPM) Market

The Malignant Pleural Mesothelioma (MPM) Market is anticipated to grow in the coming years owing to the improvement in healthcare spending across the world, rising prevalence, and the active participation of the key companies in therapeutics domain such as Sellas, Polaris Pharma, Targovax, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/